Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
EMN26
Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients
- NCT04564703 ↗
- Active, not recruiting
- Stichting European Myeloma Network
- Deep
We haven't built an HCP commentary report on EMN26 (iberdomide in Multiple Myeloma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on EMN26 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 10 | |
| Podcasts | 8 | |
| X threads | 7 | |
| Bluesky threads | 2 |
The trial
ClinicalTrials.gov- Official title
- Phase II Study of Iberdomide (Cc220) Maintenance After Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma Patients
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Iberdomide
- Arms
- cohort 1 · Experimental
- cohort 2 · Experimental
- cohort 3 · Experimental
- Enrollment
- 160 (estimated)
- Primary outcomes
- Efficacy: rate of improvement in response with iberdomide maintenance after autologous stem cell transplantation (ASCT)
- Rate of dose reductions/discontinuations with iberdomide maintenance after ASCT
- Sponsor
- Stichting European Myeloma Network with Healt Data Specialists - HeaDS (CRO), EMN Research Italy Impresa Sociale Srl
- Start
- Feb 22, 2021
- Primary completion
- Jul 27, 2023
- Results posted
- No
- Registry record
- NCT04564703 · updated Jul 16, 2026